l'Open Innovation aujourd'hui by Open2Innovation.net c'est bien évidemment :

Diotheris

voir toutes

Diotheris

BioTech

We create bacterial therapies of the human skin and mucosal microbiome against pathogenic bacteria. Our first suite of products (NASOFLORE line) targets Staphyloccocus aureus / MRSA (Methicillin resistant S aureus). The products based on live bacteria identified in our clinical and in vitro studies do not generate emergence of antibiotic resistance.

microbiote